One validated downstream target of UGT8 is LIPA, which encodes a lysosomal cholesterol-metabolizing enzyme associated with genetic polymorphisms that affect plasma 24S–hydroxycholesterol/cholesterol levels in AD patients [51] (Fig. 5d). This evidence concerns the gene UGT8 and Alzheimer disease.